RRC ID 77417
著者 Masuda T, Sato Y, Huang YL, Koi S, Takahata T, Hasegawa A, Kawai G, Kannagi M.
タイトル Fate of HIV-1 cDNA intermediates during reverse transcription is dictated by transcription initiation site of virus genomic RNA.
ジャーナル Sci Rep
Abstract Retroviral reverse transcription is accomplished by sequential strand-transfers of partial cDNA intermediates copied from viral genomic RNA. Here, we revealed an unprecedented role of 5'-end guanosine (G) of HIV-1 genomic RNA for reverse transcription. Based on current consensus for HIV-1 transcription initiation site, HIV-1 transcripts possess a single G at 5'-ends (G1-form). However, we found that HIV-1 transcripts with additional Gs at 5'-ends (G2- and G3-forms) were abundantly expressed in infected cells by using alternative transcription initiation sites. The G2- and G3-forms were also detected in the virus particle, although the G1-form predominated. To address biological impact of the 5'-G number, we generated HIV clone DNA to express the G1-form exclusively by deleting the alternative initiation sites. Virus produced from the clone showed significantly higher strand-transfer of minus strong-stop cDNA (-sscDNA). The in vitro assay using synthetic HIV-1 RNAs revealed that the abortive forms of -sscDNA were abundantly generated from the G3-form RNA, but dramatically reduced from the G1-form. Moreover, the strand-transfer of -sscDNA from the G1-form was prominently stimulated by HIV-1 nucleocapsid. Taken together, our results demonstrated that the 5'-G number that corresponds to HIV-1 transcription initiation site was critical for successful strand-transfer of -sscDNA during reverse transcription.
巻・号 5
ページ 17680
公開日 2015-12-3
DOI 10.1038/srep17680
PII srep17680
PMID 26631448
PMC PMC4668388
MeSH DNA, Complementary / genetics* HEK293 Cells / virology HIV-1 / genetics* HIV-1 / pathogenicity Humans Nucleocapsid Proteins / genetics Nucleocapsid Proteins / metabolism RNA, Viral / genetics* Reverse Transcription* Transcription Initiation Site*
IF 3.998
リソース情報
遺伝子材料 CSII-CMV-MCS (RDB04377)